INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 215 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.35 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | -100.0% | 2 | -99.9% | 0.00% | – |
| Q2 2023 | $1 | -50.0% | 2,083 | 0.0% | 0.00% | – |
| Q1 2023 | $2 | -33.3% | 2,083 | 0.0% | 0.00% | – |
| Q4 2022 | $3 | -99.9% | 2,083 | 0.0% | 0.00% | – |
| Q3 2022 | $4,000 | 0.0% | 2,083 | -2.0% | 0.00% | – |
| Q2 2022 | $4,000 | -42.9% | 2,126 | +1.9% | 0.00% | – |
| Q1 2022 | $7,000 | -75.9% | 2,087 | -63.9% | 0.00% | -100.0% |
| Q4 2021 | $29,000 | -73.1% | 5,788 | -61.8% | 0.00% | -80.0% |
| Q3 2021 | $108,000 | -25.0% | 15,151 | -2.6% | 0.01% | -16.7% |
| Q2 2021 | $144,000 | 0.0% | 15,558 | +0.2% | 0.01% | -14.3% |
| Q1 2021 | $144,000 | +3.6% | 15,531 | -1.2% | 0.01% | -12.5% |
| Q4 2020 | $139,000 | -18.7% | 15,722 | +6.5% | 0.01% | -27.3% |
| Q3 2020 | $171,000 | -19.0% | 14,767 | +88.5% | 0.01% | -26.7% |
| Q2 2020 | $211,000 | – | 7,836 | +783500.0% | 0.02% | – |
| Q1 2020 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Defender Capital, LLC. | 648,800 | $1,920,000 | 1.55% |
| Round Table Services, LLC | 339,391 | $998,000 | 0.31% |
| ARK Investment Management | 3,955,017 | $11,628,000 | 0.29% |
| Nikko Asset Management Americas, Inc. | 4,884,100 | $14,359,000 | 0.28% |
| WASATCH ADVISORS LP | 6,735,726 | $19,803,000 | 0.19% |
| Cedar Brook Financial Partners, LLC | 41,500 | $122,000 | 0.06% |
| Unified Trust Company, N.A. | 15,716 | $46,000 | 0.03% |
| Bay Colony Advisory Group, Inc d/b/a Bay Colony Advisors | 13,500 | $40,000 | 0.03% |
| STONERIDGE INVESTMENT PARTNERS LLC | 16,914 | $50,000 | 0.02% |
| Sumitomo Mitsui Trust Holdings, Inc. | 4,884,100 | $14,359,000 | 0.01% |